EHP-102

EHP-102
Clinical data
Other names	EHP102; VCE-003.2; VCE003.2
Routes of; administration	Oral
Drug class	Cannabinoid CB2 receptor agonist; PPARγ agonist
Identifiers
	IUPAC name 3-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-(ethylamino)-4-hydroxy-6-pentylcyclohexa-3,5-diene-1,2-dione;
CAS Number	1807652-43-2;
PubChem CID	91864651;
DrugBank	DB16933;
UNII	FDH1SMY691;
Chemical and physical data
Formula	C23H35NO3
Molar mass	373.537 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCC1=C(C(=C(C(=O)C1=O)C/C=C(\C)/CCC=C(C)C)O)NCC;
	InChI InChI=1S/C23H35NO3/c1-6-8-9-13-18-20(24-7-2)21(25)19(23(27)22(18)26)15-14-17(5)12-10-11-16(3)4/h11,14,24-25H,6-10,12-13,15H2,1-5H3/b17-14+; Key:MRCQPMQBCKEOCU-SAPNQHFASA-N;

EHP-102, also known as VCE-003.2, is a cannabinoid CB₂ receptor agonist and PPARγ agonist which is under development for the treatment of Parkinson's disease and Huntington's disease.^[1]^[2]^[3]^[4] It is taken orally.^[1] The drug is a derivative of cannabigerol (CBG).^[4] It is under development by Emerald Health Sciences.^[1]^[2]^[3] As of February 2024, it is in the preclinical research stage of development for both Parkinson's disease and Huntington's disease, but no recent development has been reported for Huntington's disease.^[1]^[2]^[3]

References

1 2 3 4 5 "EHP 102". AdisInsight. 28 February 2024. Retrieved 2 June 2026.
1 2 3 "Delving into the Latest Updates on EHP-102 with Synapse". Synapse. 24 May 2025. Retrieved 2 June 2026.
1 2 3 Shaffer C (1 March 2020). "Medical Cannabis Pioneers Stake Their Claims: Across the medical cannabis frontier, natural cannabinoids, synthetic analogues, rationally designed ligands, and prodrugs are being developed". Genetic Engineering & Biotechnology News. 40 (3): 52–55. doi:10.1089/gen.40.03.14. ISSN 1935-472X.
1 2 Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, et al. (July 2016). "VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease". Scientific Reports. 6 29789. doi:10.1038/srep29789. PMC 4949444. PMID 27430371.

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

[AdisInsight-1] 1 2 3 4 5 "EHP 102". AdisInsight. 28 February 2024. Retrieved 2 June 2026.

[Synapse-2] 1 2 3 "Delving into the Latest Updates on EHP-102 with Synapse". Synapse. 24 May 2025. Retrieved 2 June 2026.

[Shaffer2020-3] 1 2 3 Shaffer C (1 March 2020). "Medical Cannabis Pioneers Stake Their Claims: Across the medical cannabis frontier, natural cannabinoids, synthetic analogues, rationally designed ligands, and prodrugs are being developed". Genetic Engineering & Biotechnology News. 40 (3): 52–55. doi:10.1089/gen.40.03.14. ISSN 1935-472X.

[Díaz-AlonsoParaíso-LunaNavarrete2016-4] 1 2 Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, et al. (July 2016). "VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease". Scientific Reports. 6 29789. doi:10.1038/srep29789. PMC 4949444. PMID 27430371.

[1]

[2]

[3]

[4]

v t e PPARTooltip Peroxisome proliferator-activated receptor modulators
PPARαTooltip Peroxisome proliferator-activated receptor alpha	Agonists: 15-HETE 15-HpETE Aleglitazar Aluminium clofibrate Arachidonic acid Bezafibrate Chiglitazar Clofibrate CP-775146 Daidzein DHEA (prasterone) (in rodents) Elafibranor Etomoxir Fenofibrate Genistein Gemfibrozil GW-7647 Lanifibranor Leukotriene B₄ LG-101506 LG-100754 Lobeglitazone Muraglitazar Oleylethanolamide Palmitoylethanolamide Pemafibrate Perfluorononanoic acid Perfluorooctanoic acid Pioglitazone Saroglitazar Sodelglitazar Tesaglitazar Tetradecylthioacetic acid Troglitazone WY-14643 Antagonists: GW-6471 MK-886
PPARδTooltip Peroxisome proliferator-activated receptor delta	Agonists: 15-HETE 15-HpETE Arachidonic acid Bezafibrate Bocidelpar Daidzein Elafibranor Fonadelpar Genistein GW-0742 GW-501516 L-165,041 Lanifibranor LG-101506 Seladelpar Sodelglitazar Tetradecylthioacetic acid Tianeptine Estianeptine Antagonists: FH-535 GSK-0660 GSK-3787
PPARγTooltip Peroxisome proliferator-activated receptor gamma	Agonists: 5-Oxo-ETE 5-Oxo-15-hydroxy-ETE 15-Deoxy-Δ^12,14-prostaglandin J₂ 15-HETE 15-HpETE Aleglitazar Arachidonic acid Balaglitazone Berberine Bezafibrate Cannabidiol Cevoglitazar Chiglitazar Ciglitazone Daidzein Darglitazone Edaglitazone Efatutazone EHP-102 (VCE-003.2) Englitazone Etalocib Farglitazar Genistein GW-1929 Ibuprofen Imiglitazar Indeglitazar Lanifibranor LG-100268 LG-100754 LG-101506 Lobeglitazone Muraglitazar (muroglitazar) nTZDpa Naveglitazar Netoglitazone Oxeglitazar Peliglitazar Pemaglitazar Perfluorononanoic acid Pioglitazone Prostaglandin J₂ Ragaglitazar Reglitazar Rivoglitazone Rosiglitazone RS5444 Saroglitazar Sipoglitazar Sodelglitazar Telmisartan Tesaglitazar Tianeptine Estianeptine Troglitazone SPPARMsTooltip Selective PPARγ modulator: BADGE EPI-001 INT-131 MK-0533 S26948 Antagonists: FH-535 GW-9662 SR-202 T-0070907 Unknown: SR-1664
Non-selective	Agonists: Ciprofibrate Clinofibrate Clofibride Englitazone Etofibrate Farglitazar Netoglitazone Ronifibrate Rivoglitazone Simfibrate
See also Receptor/signaling modulators

This page was redesigned at the edge.

See also

References